跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
anti-TIM-3 antibody (cancer)
首页
药物
anti-TIM-3 antibody (cancer)
anti-TIM-3 antibody (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS
EP 3443009 B1
申请人: SYMPHOGEN AS
优先权: 2016
CN
EP
US
WO
9 件公开
COMBINATION OF BTN3A ACTIVATING ANTIBODY AND IMMUNE CHECKPOINT INHIBITORS
EP 4669429 A1
申请人: IMCHECK THERAPEUTICS
优先权: 2023
CN
EP
US
WO
4 件公开
ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
EP 3689419 A1
申请人: ANAPTYSBIO INC
优先权: 2016
CN
EP
2 件公开
Anti-human TIM-3 antibodies and methods of use thereof
US 10752688 B2
申请人: DEV CT BIOTECHNOLOGY
优先权: 2017
CN
US
2 件公开
Treating cancer by blocking the interaction of TIM-3 and its ligand
US 12227567 B2
申请人: TRUEBINDING INC
优先权: 2018
US
2 件公开
Anti-TIM-3 antibodies
US 10259874 B2
申请人: AGENCY SCIENCE TECH & RES
优先权: 2014
US
US 10435466 B2
申请人: AGENCY SCIENCE TECH & RES
优先权: 2014
US
Methods of administering anti-TIM-3 antibodies
CN 113301961 A
申请人: MERCK PATENT GMBH
优先权: 2018
CN
PHARMACEUTICAL COMBINATIONS
CN 113195539 A
申请人: NOVARTIS AG
优先权: 2018
CN
Combination therapy of anti-PD-1 active agent, anti-TIM-3 active agent and anti-LAG-3 active agent for treatment of cancer
CN 119630421 A
申请人: INCYTE CORP
优先权: 2022
CN
Pharmaceutical composition for treating lung cancer
CN 118681010 A
申请人: CHIA TAI TIANQING PHARMACEUTICAL GROUP NANJING SHUNXIN PHARMACEUTICAL CO LTD
优先权: 2023
CN
第 1 / 2 页
上一页
下一页
药物
反馈